MetaCap

GH Research (GHRS) vs MannKind (MNKD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GH Research (GHRS) has outperformed MannKind (MNKD) over the past year, gaining 25.1% versus a loss of 23.5%. Over five years, MNKD leads with a -16.8% price change compared with -21.0% for GHRS. MannKind is the larger company by market cap ($1.24 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GHRS+25.08%MNKD-23.46%
+127%+32%-63%
Nov 21, 20251 yearNov 20, 2026
GHRS-32.08%MNKD-18.95%
+61%-12%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GHRS versus MNKD key metrics
MetricGHRSMNKD
Share price$17.53$3.85
Market cap$1.20B$1.24B
1-day change-5.55%-2.53%
YTD return+38.03%-32.10%
1-year return+25.08%-23.46%
5-year return-21.00%-16.85%
Forward P/E—24.44
EPS (TTM)$-0.94$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$348.97M
Revenue growth (YoY)—+22.23%
Net income (latest FY)$-48.26M$5.86M
Gross margin—92.32%
Operating margin—11.12%
Net margin—1.68%
52-week high$31.44$6.51
52-week low$12.04$2.23
Distance from 52-week high-44.24%-40.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+144.67%+116.36%
Average volume294.69K3.96M
Shares outstanding68.68M321.64M
Employees73591
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GHRS has outperformed MNKD by 48.5 percentage points over the past year.

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About MannKind

MNKD stock →

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees

GHRS vs MNKD FAQ

Which is bigger, GH Research or MannKind?

MannKind (MNKD) is larger, with a market capitalization of $1.24B compared with $1.20B for GH Research (GHRS).

Which stock has performed better over the past year, GHRS or MNKD?

GHRS returned +25.08% over the past 12 months, compared with -23.46% for MNKD (price return, excluding dividends). Past performance does not predict future results.

Are GH Research and MannKind in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons